Browsing Institutt for klinisk medisin by Author "Yagci, Munci"

Now showing items 1-2 of 2

  • Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics 
    Richardson, Paul G.; Schjesvold, Fredrik Hellem; Weisel, Katja; Moreau, Philippe; Anderson, Larry D.; White, Darrell; Rodriguez-Otero, Paula; Sonneveld, Pieter; Engelhardt, Monika; Jenner, Matthew; Corso, Alessandro; Dürig, Jan; Pavic, Michel; Salomo, Morten; Beksac, Meral; Oriol, Albert; Lindsay, Jindriska; Liberati, Anna Marina; Galli, Monica; Robak, Pawel; Larocca, Alessandra; Yagci, Munci; Vural, Filiz; Kanate, Abraham S.; Jiang, Ruiyun; Grote, Lara; Peluso, Teresa; Dimopoulos, Meletios (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2022)
    Objective We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated ...
  • Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment 
    Oriol, Albert; Dimopoulos, Meletios; Schjesvold, Fredrik Hellem; Beksac, Meral; Facon, Thierry; Dhanasiri, Sujith; Guo, Shien; Mu, Yutian; Hong, Kevin; Gentili, Christian; Galli, Monica; Yagci, Munci; Larocca, Alessandra; Richardson, Paul; Weisel, Katja (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2023)
    Introduction A proportion of patients with multiple myeloma (MM) are older and/or have comorbidities, requiring dose adjustments. Data from OPTIMISMM (NCT01734928) supported the use of pomalidomide, bortezomib, and ...